Tevogen Inc.
TVGN · XNASCIK 1860871fmd_1ZE4JJY2VHNBH4SKMGQ7EAMS10Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Apr 21, 2021 to Jun 30, 2026, 20 periods
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Net interest income | – | – | (0) | (0) |
| Research and development | – | 4 | 31 | 11 |
| Total operating expenses | – | 9 | 54 | 26 |
| Operating income | – | (9) | (54) | (26) |
| Interest expense | – | 1 | 0 | – |
| Interest and investment income | 5 | 3 | – | – |
| Other non-operating income (expense) | 5 | 2 | – | – |
| Income tax expense | – | – | 0 | 0 |
| Net income | 4 | (60) | (14) | (26) |
| Net income to common shareholders | – | (60) | (10) | (27) |